Immunology biotech Agomab Therapeutics and eye-focused SpyGlass Pharma have both unveiled their intentions to go public, in ...

Meanwhile, another $70 million to $80 million of the IPO proceeds is expected to fund the launch a phase 1b study of its ...

The BIM-IOL is designed to be implanted during cataract surgery, tackling IOP while restoring vision, and SpyGlass is also ...

Two more biopharma companies—the hair-growth specialist Veradermics and cancer-focused Eikon Therapeutics—have announced ...

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...

Hair loss–focused Veradermics and cancer biotech Eikon follow the lead of Aktis Oncology, which last week announced a $318 ...

Biotech is dominating the (very) early 2026 deals market, whether that be startup fundings, IPOs, or mergers. Why it matters: ...

Investors are eyeing a rebound in the U.S. biotech sector in 2026, as more companies ​are expected to go public amid a ...

TheraVectys SA is considering an initial public offering in Hong Kong, according to people familiar with the matter, a rare move for a non-Chinese biotech firm despite a wave of listings in the Asian ...

Cancer drug developer Aktis Oncology announced on Thursday that it has successfully priced its upsized U.S. initial public ...

A surge in deals and financings had the industry abuzz heading into this year’s J.P. Morgan Healthcare Conference. But some ...

US$4 billion in Hong Kong in the first three weeks of 2026, with hundreds more lining up to list, Bonnie Chan says New energy ...